Literature DB >> 25364490

Hypertension in Autosomal Dominant Polycystic Kidney Disease: A Clinical and Basic Science Perspective.

Shobha Ratnam1, Surya M Nauli1.   

Abstract

BACKGROUND AND AIMS: Cardiovascular complications are major causes of morbidity and mortality in patients with autosomal dominant polycystic kidney disease (ADPKD). In particular, hypertension is insidious and remains a continuous problem that evolves during the course of the disease. Hypertension in ADPKD has been associated with abnormality in the renin-angiotensin-aldosterone system (RAAS). Early vascular changes have also been reported in young ADPKD patients. In addition, the cellular functions of mechanosensory cilia within vascular system have emerged recently. The basic and clinical perspectives of RAAS, vascular remodeling and sensory cilia are reviewed with regard to hypertension in ADPKD.

Entities:  

Keywords:  ADPKD; Angiotensin; Blood Pressure; Cardiovascular; Cilia Biology; Hypertension

Year:  2010        PMID: 25364490      PMCID: PMC4215423     

Source DB:  PubMed          Journal:  Int J Nephrol Urol        ISSN: 2008-4684


  130 in total

1.  Characterisation and expression of the PKD-1 protein, polycystin, in renal and extrarenal tissues.

Authors: 
Journal:  Kidney Int       Date:  1999-05-18       Impact factor: 10.612

Review 2.  Autoregulation of cerebral blood flow in newborn babies.

Authors:  Gorm Greisen
Journal:  Early Hum Dev       Date:  2005-05       Impact factor: 2.079

Review 3.  Hypertension in autosomal dominant polycystic kidney disease.

Authors:  A B Chapman; P A Gabow
Journal:  Kidney Int Suppl       Date:  1997-10       Impact factor: 10.545

4.  Endothelial-derived vasoactive mediators in polycystic kidney disease.

Authors:  Muna A Al-Nimri; Radko Komers; Terry T Oyama; Arohan R Subramanya; Jessie N Lindsley; Sharon Anderson
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

5.  Familial clustering of ruptured intracranial aneurysms in autosomal dominant polycystic kidney disease.

Authors:  M M Belz; R L Hughes; W D Kaehny; A M Johnson; G M Fick-Brosnahan; M P Earnest; P A Gabow
Journal:  Am J Kidney Dis       Date:  2001-10       Impact factor: 8.860

6.  Polycystin 1 is required for the structural integrity of blood vessels.

Authors:  K Kim; I Drummond; O Ibraghimov-Beskrovnaya; K Klinger; M A Arnaout
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

7.  Location of mutations within the PKD2 gene influences clinical outcome.

Authors:  N Hateboer; B Veldhuisen; D Peters; M H Breuning; J L San-Millán; N Bogdanova; E Coto; M A van Dijk; A R Afzal; S Jeffery; A K Saggar-Malik; R Torra; D Dimitrakov; I Martinez; S S de Castro; M Krawczak; D Ravine
Journal:  Kidney Int       Date:  2000-04       Impact factor: 10.612

8.  Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease.

Authors:  Tsukasa Nakamura; Takeshi Sugaya; Yasuhiro Kawagoe; Yoshihiko Ueda; Shiwori Osada; Hikaru Koide
Journal:  Am J Med Sci       Date:  2005-10       Impact factor: 2.378

9.  Increased blood pressure in transgenic mice expressing both human renin and angiotensinogen in the renal proximal tubule.

Authors:  Julie L Lavoie; Kristy D Lake-Bruse; Curt D Sigmund
Journal:  Am J Physiol Renal Physiol       Date:  2004-01-13

10.  Clinical aspects of renal transplantation in polycystic kidney disease.

Authors:  B Stiasny; D Ziebell; S Graf; I A Hauser; B D Schulze
Journal:  Clin Nephrol       Date:  2002-07       Impact factor: 0.975

View more
  8 in total

Review 1.  Current management of autosomal dominant polycystic kidney disease.

Authors:  Jacob A Akoh
Journal:  World J Nephrol       Date:  2015-09-06

2.  NOS3 gene intron 4 a/b polymorphism is associated with ESRD in autosomal dominant polycystic kidney disease patients.

Authors:  Udit Narayan Padhi; Madhubala Mulkalwar; Lakkakula Saikrishna; Henu Kumar Verma; Lvks Bhaskar
Journal:  J Bras Nefrol       Date:  2022 Apr-Jun

3.  Renal failure prevalence in poisoned patients.

Authors:  Mohammad Arefi; Fakhroddin Taghaddosinejad; Peyman Salamaty; Davood Soroosh; Hami Ashraf; Mohsen Ebrahimi
Journal:  Nephrourol Mon       Date:  2014-03-11

4.  The Roles of Primary cilia in Polycystic Kidney Disease.

Authors:  Sarmed H Kathem; Ashraf M Mohieldin; Surya M Nauli
Journal:  AIMS Mol Sci       Date:  2014

Review 5.  Autosomal dominant polycystic kidney disease and pioglitazone for its therapy: a comprehensive review with an emphasis on the molecular pathogenesis and pharmacological aspects.

Authors:  Aryendu Kumar Saini; Rakesh Saini; Shubham Singh
Journal:  Mol Med       Date:  2020-12-11       Impact factor: 6.354

6.  Arrhythmogenic Hearts in PKD2 Mutant Mice Are Characterized by Cardiac Fibrosis, Systolic, and Diastolic Dysfunctions.

Authors:  Farideh Amirrad; Rajasekharreddy Pala; Kiumars Shamloo; Brian S Muntean; Surya M Nauli
Journal:  Front Cardiovasc Med       Date:  2021-11-26

7.  Primary prevention of cardiovascular disease events with renin-angiotensin system blockade in autosomal dominant polycystic kidney disease dialysis patients: A nationwide cohort study.

Authors:  Chien-Lin Lu; Chien-Yu Lin; Lian-Yu Lin; Pau-Chung Chen; Cai-Mei Zheng; Kuo-Cheng Lu; Dong-Feng Yeih
Journal:  Medicine (Baltimore)       Date:  2021-07-02       Impact factor: 1.817

8.  Dopamine receptor antagonists as potential therapeutic agents for ADPKD.

Authors:  Parama Paul; Sreekumar Ramachandran; Sheng Xia; Jay R Unruh; Juliana Conkright-Fincham; Rong Li
Journal:  PLoS One       Date:  2019-05-06       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.